The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort by Lee, Eunjung et al.
RESEARCH ARTICLE Open Access
The association of polymorphisms in hormone
metabolism pathway genes, menopausal
hormone therapy, and breast cancer risk: a
nested case-control study in the California
Teachers Study cohort
Eunjung Lee
1, Fredrick Schumacher
1, Juan Pablo Lewinger
1, Susan L Neuhausen
2, Hoda Anton-Culver
3,
Pamela L Horn-Ross
4, Katherine D Henderson
2, Argyrios Ziogas
3, David Van Den Berg
1, Leslie Bernstein
2 and
Giske Ursin
1,5,6*
Abstract
Introduction: The female sex steroids estrogen and progesterone are important in breast cancer etiology. It
therefore seems plausible that variation in genes involved in metabolism of these hormones may affect breast
cancer risk, and that these associations may vary depending on menopausal status and use of hormone
therapy.
Methods: We conducted a nested case-control study of breast cancer in the California Teachers Study cohort. We
analyzed 317 tagging single nucleotide polymorphisms (SNPs) in 24 hormone pathway genes in 2746 non-Hispanic
white women: 1351 cases and 1395 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated
by fitting conditional logistic regression models using all women or subgroups of women defined by menopausal
status and hormone therapy use. P values were adjusted for multiple correlated tests (PACT).
Results: The strongest associations were observed for SNPs in SLCO1B1, a solute carrier organic anion transporter
gene, which transports estradiol-17b-glucuronide and estrone-3-sulfate from the blood into hepatocytes. Ten of 38
tagging SNPs of SLCO1B1 showed significant associations with postmenopausal breast cancer risk; 5 SNPs
(rs11045777, rs11045773, rs16923519, rs4149057, rs11045884) remained statistically significant after adjusting for
multiple testing within this gene (PACT = 0.019-0.046). In postmenopausal women who were using combined
estrogen-progestin therapy (EPT) at cohort enrollment, the OR of breast cancer was 2.31 (95% CI = 1.47-3.62) per
minor allele of rs4149013 in SLCO1B1 (P = 0.0003; within-gene PACT = 0.002; overall PACT = 0.023). SNPs in other
hormone pathway genes evaluated in this study were not associated with breast cancer risk in premenopausal or
postmenopausal women.
Conclusions: We found evidence that genetic variation in SLCO1B1 is associated with breast cancer risk in
postmenopausal women, particularly among those using EPT.
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Reproductive and hormonal factors, including age at
menarche, parity, number of full-term pregnancies, age at
first full-term pregnancy, breastfeeding, age at meno-
pause, body mass index (BMI), and physical activity, are
associated with breast cancer risk [1,2]. Consistent with
these observations, breast cancer risk is higher among
women with higher circulating levels of endogenous
estrogen [3-5] and among women using combined post-
menopausal estrogen and progestin therapy (EPT) [6-11].
Sex steroid hormones, whether endogenous or exo-
genous, are synthesized and metabolized by many differ-
ent enzymes (reviewed in [12]). Therefore, genetic
variation among genes regulating sex steroid hormone
levels may increase or decrease breast cancer risk by
influencing hormone metabolism. Polymorphisms in
several hormone pathway genes, including CYP19A1
and COMT, have been associated with endogenous hor-
mone levels [13-16]; however, studies investigating the
association of genetic variation in hormone metabolism
genes and breast cancer risk have generated mixed
results [14,17-29]. Recently, a large study from the
Breast and Prostate Cancer Cohort Consortium (BPC3)
comprehensively analyzed 37 steroid hormone metabo-
lism pathway genes in relation to breast cancer risk and
reported null associations [16,30], suggesting that incon-
sistencies in the literature may be due to findings
observed by chance in small studies. However, it is pos-
sible that the inconsistencies may be explained at least
partly by differences in the distribution of environmental
factors that modify the effects of genetic polymorphisms.
EPT use increases breast cancer risk to a much greater
extent than estrogen-only therapy (ET) [6-11]. There-
fore, it is important to examine EPT and ET use sepa-
rately when investigating gene-hormone therapy (HT)
interactions. To date, few studies have investigated the
gene-HT interactions by hormone formulation by using
a comprehensive single-nucleotide polymorphism
(SNP)-tagging approach. The California Teachers Study
is an effective resource to study these questions because
detailed data on hormone use were collected at baseline,
and approximately 41% and 28% of the postmenopausal
participants reported current use of EPT and ET,
respectively [31]. Thus, using data from a case-control
study nested within the California Teachers Study, we
systematically investigated whether any of 24 hormone
metabolism pathway genes or their interactions with HT
were associated with breast cancer risk.
Materials and methods
Participants
The California Teachers Study has been previously
described in detail [32]. Briefly, the California Teachers
Study is a prospective cohort of women who were cur-
rent, recent, or retired California public school profes-
sionals in 1995. By returning a baseline questionnaire in
1995-1996, 133,479 women joined the cohort and pro-
vided detailed information on menopausal status, HT
use, and other lifestyle and medical factors. The baseline
questionnaire is available on the California Teachers
Study website [33]. Cancer diagnoses in the cohort are
identified through annual linkage with the California
Cancer Registry, which identifies at least 99% of cancers
diagnosed in California [34]. The California Teachers
Study has been approved by the institutional review
boards at all participating institutions: the Cancer Pre-
vention Institute of California (CPIC), the University of
California at Irvine (UCI), the University of Southern
California (USC), and the City of Hope in accordance
with assurances filed with and approved by the US
Department of Health and Human Services.
The nested breast cancer case-control study was
designed to obtain biospecimens from breast cancer
cases and unaffected controls within the 113,590 mem-
bers of the cohort who were less than 80 years old at
baseline, had continued residence in California during
the study period (1995 to time of blood draw), and,
before 1998, had no prior history of invasive or in situ
breast cancer. Cases were women who had a histologi-
cally confirmed invasive primary carcinoma of the breast
(International Classification of Disease for Oncology
code C50 restricted to morphology codes under 8,590)
and who were 80 years old or younger between 1 Janu-
ary 1998 and 31 May 2007. One control participant per
case was randomly selected from the cohort and fre-
quency-matched to the case on age at baseline (within
5-year age groups), self-reported race/ethnicity (white,
African-American, Latina, Asian, and other), and three
broad geographic regions (that is, California Teachers
Study specimen collection centers). Cancer cases were
identified through quarterly linkages of the cohort to
the California Cancer Registry database. Control selec-
tion was conducted on a quarterly basis without replace-
ment. For each wave of control selection, a reference
date was determined (that is,J a n u a r y ,A p r i l ,J u l y ,a n d
October of each year). Nearly equal numbers of controls
were selected in each wave. One control participant had
her breast cancer diagnosed after her control selection
and was included in the analysis as both a control and a
case.
Collection of biological specimens and DNA extraction
Collection of biological specimens was conducted at
three study centers (CPIC in the northern half of Cali-
fornia and USC and UCI in the southern half). Women
who declined blood draw were asked whether they were
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DNA self-collection kit (DNA Genotek, Kanata, ON,
Canada) was mailed to the participant with informed
consent and return postage paid mailing materials.
From the 8,118 eligible participants (2,618 cases and
5,500 selected controls), we collected biological speci-
mens for 74% of the cases (1,923 cases: 1,684 blood spe-
cimens and 239 saliva specimens) and 61% of the
controls (3,350 controls: 3,012 blood specimens and 338
saliva specimens). All biologic samples were sent via
overnight courier to the UCI laboratory for DNA extrac-
tion. DNA was extracted from blood clots by using Qia-
g e nC l o t s p i nB a s k e t sa n dD N AQ I A m pD N AB l o o d
maxi kits (Qiagen Inc., Valencia, CA, USA) in accor-
dance with Qiagen protocols. DNA was extracted from
saliva samples by using the Oragene protocol (DNA
Genotek). The nested breast cancer case-control study
of the California Teachers Study has been approved by
the institutional review boards at all participating insti-
tutions, and all participants provided written informed
consent.
Tagging SNP selection and genotyping
We investigated 24 genes that are involved in female
sex steroid hormone biosynthesis, metabolism, or
excretion. Reviews on the function of these genes are
available elsewhere [12,35,36]. For 21 of these genes, a
tagging SNP approach was used (Supplementary Table
S1 in Additional file 1). For 16 of the 21 genes, we
selected linkage disequilibrium tagging SNPs across
each gene, 20 kb upstream of 5’ untranslated region
(UTR) and 10 kb downstream of 3’ UTR. The tagging
SNPs were selected to capture all common SNPs
(minor allele frequency (MAF) of at least 5%) in indivi-
duals of European ancestry with minimum pairwise R
2
of at least 0.80 by using the Snagger software [37] and
the data from the International HapMap Project for
the white CEPH (Utah residents with ancestry from
northern and western Europe) population (HapMap
release 21, July 2006, genotype build 36 [38]). Tagging
SNPs for five genes included in the present study had
been selected by BPC3 by using the TagSNPs program
[30,39]. To facilitate the comparison across studies, we
used the BPC3-selected tagging SNPs for these five
genes (Supplementary Table S1 in Additional file 1).
The BPC3-selected tagging SNPs captured all common
SNPs (MAF of at least 5%) in whites with minimum
pairwise R
2 of at least 0.8. For the remaining 3 of the
24 genes, we genotyped a few selected SNPs due to
space limitations of our genotyping platform. For
CYP19A1, the selected SNPs were shown to be asso-
ciated with circulating estrogen concentrations in a
comprehensive analysis [13] (Supplementary Table S1
in Additional file 1).
A total of 1,751 breast cancer cases and 1,697 controls
were available for genotyping. We included a random
sample of 193 replicates (105 cases and 88 controls) to
monitor reproducibility and track plate flips or switches.
The DNA samples were genotyped for the selected tag-
ging SNPs by using the Illumina Golden Gate Assay
(Illumina, Inc., San Diego, CA, USA) in the USC Core
Facility. About 10% of the genotyped samples, including
189 cases and 150 controls, had a genotyping success
rate (call rate) of less than 90% and were excluded from
the analyses. The genotyping concordance rate based on
the 160 duplicate samples with a call rate of at least
90% was 99.9%. Call rates were lower when the DNA
was obtained from saliva samples: 23% of saliva samples
and 8% of blood samples had a call rate of less than
90% and these samples therefore were excluded from
the analyses. However, the genotyping concordance after
excluding the low call rate samples was excellent for sal-
iva samples (greater than 99.9%). In addition, results
from sensitivity analyses excluding saliva samples were
similar to those using all samples. For the present study,
we also excluded 88 women (52 cases and 36 controls)
who self-reported to have had a previous history of can-
cer, leaving 1,510 cases and 1,511 controls. Because the
majority (approximately 91%) of participants were non-
Hispanic whites, we restricted the analyses to 2,746
non-Hispanic white women (1,351 cases and 1,395
controls).
Of the 355 SNPs genotyped, 332 had an SNP call rate
of at least 90%. We excluded an additional three SNPs
that had discordant readings in more than two duplicate
pairs, eight SNPs with an MAF of less than 1% among
non-Hispanic white controls, and four SNPs in COMT,
C Y P 1 1 A ,S U L T 1 A 1 ;S U L T 1 A 2 ,U G T 1 A 8not in Hardy-
Weinberg equilibrium (P < 0.001); thus, we analyzed
317 SNPs in the present study.
For 19 of the 20 genes for which we used the tagging
SNP approach, the genotyped tagging SNPs efficiently
captured 70% to 100% of all common SNPs (MAF of
greater than 5%) in the HapMap dataset of European
ancestry (HapMap release 24, genotype build 36) with
pairwise R
2 of at least 0.80 (Supplementary Table S1 in
Additional file 1). We did not have sufficient tagging
coverage for CYP21A2.
Imputation
W ei m p u t e dS N P si ng e n er e g i o n sw h e r ew ef o u n da
statistically significant association (P < 0.01 before mul-
tiple testing correction) with breast cancer risk among
all women or among subgroups defined by menopausal
status. To do this, we used publicly available HapMap
genotype data in the CEPH population as the reference
sample (HapMap release 24, genotype build 36 [38]) and
MACH 1.0 [40]. We excluded imputed SNPs when the
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2 was less than
0.30 [40].
Statistical analyses
We used conditional logistic regression models with
strata defined by 5-year age group and the three speci-
men collection centers to estimate the odds ratios
(ORs), 95% confidence intervals (CIs), and P values asso-
ciated with each SNP by using log-additive models. The
results did not change after further adjustment for
potential confounders including menopausal status (pre-
menopausal, postmenopausal, and unknown), HT use
status at baseline (never used HT, currently using ET,
currently using EPT, used HT in the past, and
unknown), BMI (less than 25, 25 to less than 30, at least
30 kg/m
2,a n du n k n o w n ) ,p a r i t y( 0 ,1t o2 ,a tl e a s t3 ,
and unknown), and oral contraceptive use (never, ever,
and unknown). Therefore, we presented the results from
the conditional logistic regression models not adjusting
for these potential confounders.
We performed subgroup-specific analyses by meno-
pausal status and, among postmenopausal women, by
HT use at baseline, defining the groups of interest as
never used HT, currently using ET, and currently using
EPT. We calculated P for interaction by likelihood ratio
test comparing the model with and without the product
term of genotype (0, 1, and 2 copies of minor allele, as
ordinal variable) and menopausal status or HT use. The
interaction tests for HT use were done separately for
current EPT use (as compared with never HT use) and
for current ET use (as compared with never HT use).
Results
A greater proportion of breast cancer cases than con-
trols were currently using EPT at baseline; a lower pro-
portion of cases than controls had high parity. Cases
also had slightly earlier age at menarche than control
women (Table 1).
Evaluation of the q-q plot of the P values for the asso-
ciation between the 317 SNPs in the 24 hormone meta-
bolism genes and breast cancer risk showed no evidence
of systematic bias (Supplementary Figure S1 in Addi-
tional file 2).
We observed statistically significant associations at a
P value of less than 0.01 with two SNPs in SLCO1B1
and one SNP in HSD17B4 in the overall analysis
(Table 2). However, after multiple comparisons were
corrected for, none of these associations was statisti-
cally significant. For postmenopausal women, 10 SNPs
in SLCO1B1 were associated with breast cancer risk
with an uncorrected P value of less than 0.01. Of
these, the associations for SNPs rs11045773,
rs11045777, rs16923519, rs4149057, and rs11045884
remained statistically significant after correction for
multiple testing within the gene (within-gene PACT <
0.05). However, after multiple testing across all genes
was corrected for, none of these associations was sta-
tistically significant. The ORs and 95% CIs associated
for all tested SNPs are provided in Supplementary
Table S2 in Additional file 3. There was some evidence
that, of these, rs4149013 in SLCO1B1 was associated
with breast cancer risk in postmenopausal women (OR
1.39, 95% CI 1.07 to 1.81; uncorrected P = 0.015).
When examining by HT use, we observed a strong
association between several SNPs in SLCO1B1 and post-
menopausal breast cancer risk in current EPT users
(Table 3). Breast cancer risk among postmenopausal
women who were using EPT at baseline increased more
than twofold per minor allele of rs4149013 (OR 2.31,
95% CI 1.47 to 3.62; P = 0.0003, within-gene PACT =
0.002). This association was statistically significant even
after PACT adjustment across all SNPs studied (PACT =
0.023). The P value for interaction (EPT versus never
HT use) was 0.019 (not corrected for multiple testing).
When we combined the homozygous and heterozygous
minor allele carriers (that is, a dominant genetic model),
we observed similar OR estimates and P values (OR
2.43, 95% CI 1.53 to 3.85; P = 0.0002) (Supplementary
Table S3 in Additional file 4). We did not observe any
significant associations in never HT users and ET users.
There was no statistically significant difference in effects
when stratifying by estrogen receptor status.
Discussion
In this case-control study nested within the California
Teachers Study cohort, genetic variation in only 1
(SLCO1B1) of 24 genes in the hormone metabolism
pathway genes was associated with breast cancer risk.
SLCO1B1, a gene involved in the hepatic uptake of
female sex steroids, seemed to be associated with breast
cancer risk among postmenopausal women. This asso-
ciation was statistically significant after correcting for
multiple testing within the gene but was not statistically
significant after we corrected for multiple testing across
genes. However, there was also an indication that EPT
may interact with SNPs in SLCO1B1;o n ev a r i a n ti n
SLCO1B1 (rs4149013) was statistically significantly asso-
ciated with breast cancer risk in EPT users.
Our findings of no association between SNPs in hor-
mone metabolism pathway genes and breast cancer risk
are consistent with the results from other large studies
such as BPC3 [13,29,30,41] and meta-analyses of
selected functional SNPs in CYP1A1 [23], SULT1A1
[42,43], CYP1B1 [44,45], and COMT [46], although two
smaller meta-analyses of selected functional SNP in
COMT supported an association in Caucasian popula-
tions [47,48]. Although a few studies have suggested
associations between genetic polymorphisms in other
Lee et al. Breast Cancer Research 2011, 13:R37
http://breast-cancer-research.com/content/13/2/R37
Page 4 of 11Table 1 Characteristics of the study participants at time of joining the cohort
Control Case
Characteristics Number Percentage Number Percentage
Number 1,395 1,351
Mean age ± SD, years 56.1 ± 9.5 55.0 ± 9.4
Menopausal status
Premenopausal 347 25.3 364 27.5
Postmenopausal
a 1,024 74.7 962 72.5
Unknown 24 - 25 -
HT use among postmenopausal women
Never used HT 153 15.8 112 12.4
Current ET use 277 28.7 230 25.5
Current EPT use 401 41.5 468 51.9
Former ET or EPT use 122 12.6 80 8.9
Ever used progestin alone 13 1.3 12 1.3
Unknown 58 - 60 -
Parity/total number of FTPs
Nulligravid 221 16.1 219 16.4
Gravid, nulliparous 61 4.4 66 4.9
1 FTP 159 11.6 174 13.0
2 FTPs 487 35.4 472 35.3
3 FTPs 274 20.0 277 20.7
4+ FTPs 172 12.5 128 9.6
Unknown 21 - 15 -
Body mass index
< 25 kg/m
2 765 54.8 778 58.9
25 to < 30 kg/m
2 387 27.7 384 29.1
30+ kg/m
2 195 14.0 159 12.0
Unknown 48 - 30 -
Age at menarche
≤10 years 100 7.3 100 7.5
11-12 years 600 43.6 599 44.8
13-14 years 565 41.0 542 40.6
15-16 years 102 7.4 82 6.1
17+ years 10 0.7 13 1.0
Unknown/Never had menarche 18 - 15 -
Family history of breast cancer (first-degree relative)
No 1,167 86.1 1,085 82.1
Yes 189 13.9 236 17.9
Unknown 39 - 30 -
History of breast biopsy
No 1,086 77.8 1,034 76.5
Yes 309 22.2 317 23.5
Screening mammograms within last 2 years
No 138 10.0 146 10.9
Yes 1,241 90.0 1,193 89.1
Unknown 16 - 12 -
aIncludes perimenopausal women. EPT, estrogen progestin combined therapy; ET, estrogen therapy; FTP, full-term pregnancy; HT, hormone therapy; SD, standard
deviation.
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Page 7 of 11hormone pathway genes, including CYP11A [25,26],
CYP1A1/CYP1A2 [49,50], CYP1B1 [51,52], SULT1E1
[53], or COMT [54], many of these associations were
not observed consistently [30,49,50,55-57]. In addition,
the few studies other than BPC3 that have investigated
polymorphisms in CYP2C9 [51], CYP3A4 [49,51,56],
HSD17B2 [58], SRD5A1 [56], and UGT2B7 [51], in rela-
tion to breast cancer risk among Caucasian populations,
have reported no associations. However, a recent study
using admixture maximum likelihood (AML)-based glo-
bal tests reported that genetic variation in androgen-
estrogen conversion pathway was associated with breast
cancer risk, although no single SNP was significant after
correcting multiple testing [59].
To our knowledge, no studies have investigated
genetic variation in SLCO1B1 and breast cancer risk by
hormone therapy use. SLCO1B1,a l s ok n o w na sOATP-
C or SLC21A6, is expressed in the liver and plays an
important role in transporting drugs and endogenous
substrates from the blood into the hepatocytes (reviewed
in [60]). Endogenous substrates of SLCO1B1 include
steroid hormone conjugates such as estradiol-17b-glu-
curonide and estrone-3-sulfate [61,62]. Serum estrone
sulfate (E1S) is a major form of circulating estrogen in
postmenopausal women and can be converted to estra-
diol in breast tissue [63]. E1S is also a major component
of conjugated equine estrogens, the estrogen component
of the predominant (prior to 2002) HT regimens in the
US [64]. Genetic variation in SLCO1B1 has been shown
to decrease the uptake of E1S and estradiol glucuronide
in several [61,65] but not all [66] studies. Furthermore,
one study has shown that genetic variation in SLCO1B1
is associated with blood E1S levels in Caucasians [61],
suggesting that genetic variation in SLCO1B1 may inter-
act with HT use. Rs4149013 is located near the 5’ end
of SLCO1B1. The functional significance of this variant
is not known, but even if there is none, this variant
could be linked to a causal allele.
In the publicly available Cancer Genetic Markers of
Susceptibility (CGEMS) breast cancer data [67], we
found additional support implicating SLCO1B1.I n
CGEMS, five genotyped SNPs in SLCO1B1 (rs704166,
rs852550, rs852549, rs7489119, and rs2306283) were
associated with breast cancer risk with a P value of less
than 0.05. These 5 SNPs, as imputed genotypes, were
null in our dataset (data not shown), but this could be
due to misclassification from imputation or false-posi-
tive associations across both CGEMS and our data.
However, our findings and those of CGEMS, combined
with the previous literature on the role of this gene in
affecting estrone absorption, suggest that further investi-
gation of the role of SLCO1B1 genetic variation and its
interaction with EPT on breast cancer risk is warranted.
The strengths of this study include the systematic
investigation of a large number of hormone metabolism
genes and the detailed information on HT use collected
at baseline. A limitation of our study was the inability
to genotype all tagging SNPs for several of the genes of
interest, including AKR1C4, ARSC, and CYP19A1. Thus,
we cannot exclude the possibility that the lack of asso-
ciations for these loci was due to incomplete tagging.
Overall, we had 80% statistical power to detect ORs
ranging from 1.17 to 1.40 for SNPs with an MAF of
0.05 to 0.49 by using log-additive models and an alpha
of 0.05. For the subset analyses among postmenopausal
women, the minimum detectable OR ranged from 1.20
to 1.46 for SNPs with an MAF of at least 0.05. The sta-
tistical power to detect associations in premenopausal
women or to detect interactions with menopausal status
or HT use was limited. Another limitation of this study
is that HT use status assessed at baseline may have
changed during follow-up. The participation rates
(donating biological specimens for this nested case-con-
trol study) among the potentially eligible cohort mem-
bers were moderate (74% for cases and 61% for
controls). However, it is unlikely that the participation
was differential according to genotype and case status,
and thus selection bias is unlikely to have influenced
our findings.
Conclusions
Common genetic variations in SLCO1B1 may be asso-
ciated with breast cancer risk in postmenopausal
women, particularly in EPT users. The known effects of
variants in SLCO1B1 on estrogen metabolism suggest
that further study of the role of SLCO1B1 is warranted.
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